Mei Tang, Amit Garg, Peter L Bonate, Jonathan E Rosenberg, Maria Matsangou, Takeshi Kadokura, Akihiro Yamada, Mary Choules, Janet Pavese, Masanori Nagata, Daisuke Tenmizu, Akira Koibuchi, Nakyo Heo, Lu Wang, Tomasz Wojtkowski, William D Hanley, Srinivasu Poondru
Enfortumab vedotin is an antibody-drug conjugate comprised of a human monoclonal antibody directed to Nectin-4 and monomethyl auristatin E (MMAE), a microtubule-disrupting agent. The objectives of this review are to summarize the clinical pharmacology of enfortumab vedotin monotherapy and demonstrate that the appropriate dose has been selected for clinical use. Pharmacokinetics (PK) of enfortumab vedotin (antibody-drug conjugate and total antibody) and free MMAE were evaluated in five clinical trials of patients with locally advanced or metastatic urothelial carcinoma (n = 748)...
April 12, 2024: Clinical Pharmacokinetics